Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Muthu N. Kumaran"'
Autor:
Lorna Rodriguez-Rodriguez, Paula B. Caffrey, Muthu N. Kumaran, Mira Hellmann, Wilberto Nieves-Neira, Brian Buckley, Michael P. Kane, Murugesan Gounder, Darlene Gibbon, Gerald D. Frenkel, Mihae Song, Weichung Shih, Ami Vaidya
Publikováno v:
Gynecologic oncology. 150(3)
Purpose Preclinical studies performed in our laboratory have shown that high-dose selenium inhibits the development of carboplatin drug resistance in an ovarian cancer mouse xenograft model. Based on these data, as well as the potential serious toxic
CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination
Autor:
Roman P. Wernyj, Abhilash K. Ravindranath, Lorna Rodriguez-Rodriguez, Muthu N. Kumaran, Swayamjot Kaur, Elaine T. Lim, Rigel Chan, Karl E. Miletti-González, Kiran Madura
Publikováno v:
Oncotarget
Here we demonstrate that a ubiquitin E3-ligase, FBXO21, targets the multidrug resistance transporter, ABCB1, also known as P-glycoprotein (P-gp), for proteasomal degradation. We also show that the Ser291-phosphorylated form of the multifunctional pro
Autor:
Marina Chekmareva, Roman P. Wernyj, Kathleen W. Scotto, Muthu N. Kumaran, Gregory D. Miles, Elaine T. Lim, Karl E. Miletti-González, Michael Reiss, Kyle A. Murphy, Elisa V. Bandera, Swayamjot Kaur, Rigel Chan, Debra S. Heller, David J. Foran, Wenjin Chen, Abhilash K. Ravindranath, Lorna Rodriguez-Rodriguez
Publikováno v:
Journal of Biological Chemistry. 287:18995-19007
CD44 is a multifunctional cell receptor that conveys a cancer phenotype, regulates macrophage inflammatory gene expression and vascular gene activation in proatherogenic environments, and is also a marker of many cancer stem cells. CD44 undergoes seq
Autor:
Mira Hellman, Brian Buckley, Lorna Rodriguez-Rust, Wilberto Nieves-Neira, Murugesan Gounder, Mihae Song, Michael P. Kane, Darlene Gibbon, Muthu N. Kumaran, Ami Vaidya
Publikováno v:
Cancer Research. 78:CT025-CT025
PURPOSE: The effectiveness of standard-of-care platinum-taxane chemotherapy in the treatment of patients with advanced gynecologic cancers is limited by the development of chemotherapy resistance in nearly all patients. Based on our preclinical findi